2023
- Key patent for the T-Cube bispecific antibody platform granted in the United States
- Initiation of patient enrollment for Phase III trial of IBI302 for nAMD, originated by AP Bio and licensed to Innovent.
- Patents for AP505 granted in the United States and EPC
- APBio listed on TPEx Emerging Stock Board (6945.TW)
- Enrollment of the first patient for Phase I trial of AP203.
- Patient enrollment started for the Phase I trial of AP505/B1962 which was licensed to Tasly Pharmaceutical Group for China right
2022
- Series C round of $25 Million was closed
- AP505 patents granted in Australia and Korea
- AP505 was approved by the China NMPA for entering Phase I clinical trial
- AP203 has been selected as a 'Index Case' by the Center for Drug Evaluation (CDE)
- AP203 was approved by both of the US FDA & TFDA to initiate Phase I trial
2021
- Patient enrollment started for the Phase II trial of IBI302 for nAMD, originated by AP Bio and licensed to Innovent.
- AP505 patents granted in Taiwan and Russia
2020
- Completion of Phase I clinical trial for IBI302 in China
- Series B round of $22 Million was closed successfully
2019
- AP505/B1962 was licensed out to Tasly Biopharmaceutical for development, production, and marketing rights in China, Hong Kong and Macao
2018
- OBI Pharma acquired 67% in equity of AP Biosciences Inc.
- Successfully secured $3 Million in funding for a Bridge round
2017年
- Development & validation of the T-cube bispecific antibody platform
2016
- Approval of the Small Business Innovation Research (SBIR) Phase II application
2015
- Construction of the fully human Omni-Mab Naïve Antibody Phage Display Library
- Approval of the Small Business Innovation Research (SBIR) Phase I application
2014
- Successfully raised $2 Million in funding for A2 round
2013
- Establishment of AP Biosciences at Nangang Biotech Incubator, Taipei, Taiwan
- Successfully raised $1 Million in funding for A1 round.
